Target intelligence / Profile preview

Staphylococcus aureus bi-component leukocidin (Luk)

Target
Luk
Molecular classification
Bacterial exotoxin, Pore-forming toxin
01

Overview

Staphylococcus aureus bi-component leukocidins are a family of potent exotoxins secreted by S. aureus to destroy host immune cells, particularly neutrophils and macrophages [Nature Reviews Microbiology, 2014]. These toxins consist of two distinct protein subunits, the S-component and the F-component, which work synergistically to form heptameric or octameric pores in the plasma membrane of target cells [UniProt]. By lysing leukocytes, these toxins facilitate immune evasion and promote the spread of infection [PubMed: 23913162]. They play a critical role in the pathogenesis of severe conditions such as necrotizing pneumonia and deep-seated skin infections [StatPearls]. Specific leukocidins, such as Panton-Valentine Leukocidin (PVL), target host receptors like C5aR1 to initiate pore formation [PubMed: 23913162]. Therapeutic strategies focus on neutralizing these toxins using monoclonal antibodies, such as the ASN100 cocktail, to prevent tissue damage and support the host's immune response [Journal of Infectious Diseases, 2018]. These toxins are significant targets in the development of treatments for multidrug-resistant S. aureus (MRSA) infections.

Other names
Panton-Valentine leukocidinPVLGamma-hemolysinLukABLukGHLukEDBi-component pore-forming toxinHlgABC
02

Mechanism of action

Neutralization of toxin subunits to prevent receptor binding and pore formation

03

Biological functions

Immune evasionCytolysisPore formationLeukocyte destruction
04

Disease associations

InfectionNecrotizing pneumoniaSkin and soft tissue infectionSepsis
05

Safety considerations

Strain-specific toxin profilesRedundancy of virulence factorsRapid tissue necrosis
06

Interacting drugs

ASN100

3 more in the full profile.

07

Biomarkers

lukS-PV genelukF-PV geneToxin expression levels

Beyond the preview

Go deeper on Staphylococcus aureus bi-component leukocidin (Luk).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Staphylococcus aureus bi-component leukocidin (Luk).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call